The concept of tumor growth dependent on angiogenesis began in the early 1970s, but its importance was not taken seriously. In the past decade, due to the discovery of the role of angiogenic factors in angiogenesis, and the important influence of angiogenesis on tumor growth and invasion, especially on the early stage of tumor development, tumor tube formation has become one of the hotspots of tumor research in recent years. Treatment has opened up a new line of thinking. Angiogenesis refers to the growth of new capillary blood vessels derived from existing capillaries and post-capillary venules. Tumor angiogenesis is an extremely complex process, which generally includes steps including vascular endothelial matrix degradation, endothelial cell migration, endothelial cell proliferation, endothelial cell tube branching to form a vascular ring, and formation of a new basement membrane. Due to the abnormal structure and function of the neovascularization of the tumor tissue, and the vascular matrix is imperfect, the microvascular is prone to leakage, so the tumor cells do not need to undergo a complicated invasion process and directly penetrate into the blood vessel to enter the bloodstream and are distant. The site forms a metastasis. More and more studies have shown that benign tumors have rare angiogenesis and slow blood vessel growth; most malignant tumors have dense angiogenesis and rapid growth. Therefore, angiogenesis plays an important role in the development and metastasis of tumors, and inhibition of this process will significantly prevent the development and spread of tumor tissue (Carmeliet P, 2005). Studies have shown that the growth and maturation of new blood vessels is a fairly complex and coordinated process. The formation and development of blood vessels depends on the dynamic balance of angiogenesis-promoting factors and inhibitors. It requires the interaction of cells with cells, cells and matrix. A series of receptors are activated and regulated by a variety of pro-angiogenic factors and angiogenesis inhibitors. With the deep understanding of the angiogenesis and function of solid tumors, the discovery of a large number of pro-angiogenic growth factors and angiogenesis inhibitors has made people realize that the growth of blood vessels in tumors is also regulatable, and VEGF secreted by tumor cells themselves. Angiopoietin (Ang) induces tumor angiogenesis. More than 20 pro-angiogenic growth factors such as VEGF, bFGF, IGF-1, TNF-α, TNF-β, and platelet-derived growth factor (PDGF) have been found. Among them, VEGF and its receptor (VEGFR) are the most important tumor growth-promoting factors discovered at present, which can promote the proliferation, migration and survival of tumor vascular endothelial cells, increase the permeability of tumor neovascularization, and process the tumor angiogenesis. It plays a key role in which VEGF165 has the strongest pro-angiogenic effect, and it mainly plays an important role in binding to VEGFR-2. A variety of regulatory factors can directly or indirectly affect the transduction of VEGF and its receptor signaling, and neuroplin-1 can act as a co-receptor to bind to VEGF165, thereby enhancing the binding ability of VEGF165 to VEGFR-2 and promoting tumor angiogenesis. Hypoxia-induced tumor cells produce a large number of hypoxia-inducible factor-1 (HIF-1), up-regulate the expression of VEGF and its receptors, thereby promoting the formation of tumor neovascularization. bFGF, IGF-1, TNF-α, TNF-β and PDGF can increase the expression of VEGF in specific tumors in vitro, suggesting that the regulation of angiogenesis by these factors is partly achieved by up-regulating VEGF expression. bFGF can also affect endothelial cell migration, promote vascular lumen formation, stimulate endothelial cells to secrete collagenase, and degrade the basement membrane to facilitate neovascularization (Ferrara N, 2005). Following VEGF, a second family of pro-angiogenic factors, Ang and its receptor, was discovered. So far, four members of this family, Ang1-4, Ang-1, have been found to be pro-angiogenic factors secreted by tumor cells. Ang receptor Tie is an endothelial cell-specific tyrosine kinase receptor mainly distributed on the surface of endothelial cells and hematopoietic cells. Ang1~4 specifically acts on endothelial cells and has a strong pro-angiogenic activity. Tie-1 and Tie-2 receptors and Tie-2 ligands (Angl, Ang2) play important roles in embryonic angiogenesis and angiogenesis. Activation of the Tie-2/Ang-1 signaling pathway induces capillary sprouting, recruits perivascular cells and smooth muscle cells, maintains vascular stability, and activates endothelial cell phospholipid muscle kinase (PI3), making the apoptosis inhibitor survivin Increased production against apoptosis of endothelial cells. The Ang and VEGF families complement and coordinate each other during angiogenesis. VEGF plays a key role in the early stages of angiogenesis, while the Ang family plays an important role in late vascular maturation and further stabilization (Ribatti D, 2009; Tan A, 2010; Le Bourhis X, 2010). [The stage and characteristics of angiogenesis] The newly formed capillaries are composed of endothelial cells and epithelial cells, and these two cells have the ability to form a complete capillary network. In vivo, with signal transduction for differentiation, angiogenesis proceeds according to endothelial cell activation, proliferation, migration, and lumen formation. Endogenous or exogenous factors such as hypoxia that affect tumor mites promote the release of cytokines. The quiescent endothelial cells are activated by the cytokine released by the host or the tumor (stage I), specific cell proliferation (phase II), and move along the fiber network of the angiogenic stimulation source to form the aligned cell line (stage III), and finally the blood vessels The buds form a lumen-like structure, and the cells enter a stationary phase after exiting the cell cycle. Cross-linking of intracellular vesicles by adhesion between cells results in a clear lumen (stage IV). The descending angle of the extracellular matrix is an important part of the neovascular infiltration, mainly by changing the balance between proteolytic enzymes. The proteolysis and fibrinolysis of the extracellular matrix are two functions of the epithelial cells. Epithelial cells are also thought to be involved in the production of growth factors and inhibitors. Cell adhesion receptors move into vascular cells by interacting with extracellular matrix adhesion proteins such as collagen and fibronectin. The extracellular matrix can also act as a growth factor, particularly in the storage pool of aFGF, bFGF. Since the proliferating capillary basement membrane is incomplete, the infiltrating blood vessels in the tumor are "leakage". At the same time, vascular endothelial growth factor (VEGF) increases vascular permeability through the action of a series of cytoplasmic vesicles or vesicles that are interconnected by lumen and lumen surfaces. In normal tissues, it may play a role in regulating the basic permeability of microvessels, whereas for microvessels of tumors, this property is associated with the production of ginseng ginseng and ascites.


Amino compound >
Oxy-containing amino compound Cycloalkylamines, aromatic monoamines, aromatic polyamines and derivatives and salts thereof Acyclic monoamines, polyamines and their derivatives and salts Amide compound Sulfonic acid amino compound
Alcohols, phenols, phenolic compounds and derivatives >
2-cycloalcohol Halogenated, sulfonated, nitrated or nitrosated derivatives of alcohols Extremely halogenated, sulfonated, nitrated or nitrosated derivatives of phenols Phenol and its halogenated, sulfonated, nitrated or nitrosated derivatives Acyclic alcohol
Nitrogen-containing compound
Nitrile compound
Organic derivative of hydrazine or hydrazine
Terpenoid
Ether compounds and their derivatives >
Ether, ether alcohol Halogenation, sulfonation, nitration or nitrosation of ethers, ether alcohols, ether phenols
Aldehyde
Carboxylic compounds and derivatives >
Cyclic carboxylic acid Halogenation, sulfonation, nitration or nitrosation of carboxylic acids Halogenation, sulfonation, nitration or nitration of carboxylic anhydrides Carboxylic acid halide Carboxylic esters and their derivatives Salt of carboxylic acid ester and its derivatives Acyclic carboxylic acid
Hydrocarbon compounds and their derivatives >
Aromatic hydrocarbon Cyclic hydrocarbon Hydrocarbon sulfonate Hydrocarbon halide Hydrocarbon nitrite Acyclic hydrocarbon
Ketone compound
Alkyl ureas and their derivatives and salts
Inorganic acid ester
Heterocyclic compound
Diazo, azo or azo compound
Organosilicon compound
Organometallic compound >
Organic palladium Organic germanium, cobalt, strontium, barium, gallium, germanium, germanium, germanium, germanium, etc. Organic calcium Zirconium Organic potassium Organic Organic lithium Organic Organic aluminum Organotin Organic manganese Organic sodium Organic nickel Organic titanium Organic iron Organic copper Organotin Organic zinc Organic Organic Organic germanium, mercury, silver, platinum, etc. Organic germanium, antimony, bismuth, tungsten, antimony, bismuth, lead, vanadium, molybdenum, chromium, antimony, etc.
Organic sulfur compound
Organic phosphine compound
Organometallic salt
Organic fluorine compound >
Fluorobenzoic acid series Fluorobenzonitrile series Fluorobenzaldehyde series Fluorobenzyl alcohol series Fluoroanisole series Fluoroaniline series Fluorophenylacetic acid series Fluorophenol series Fluorobenzoic acid series Fluoronitrobenzene series Fluoropyridine series Potassium fluoroborate series Fluorobenzyl alcohol series Fluorotoluene series Fluorine red series Fluoroethane series Fluoropropane series
Respiratory medication >
Asthma Other respiratory medications Peony Antitussive
Hormone and endocrine-regulating drugs >
Birth control pills Pituitary hormone Estrogen and progestogen drugs Adrenocorticotropic drugs Gonadotropin Thyroid hormone and antithyroid drugs other Prostaglandins Adrenal corticosteroids Androgen and anabolic hormone drugs Pancreatic hormones and other blood sugar regulating drugs Treatment of male erectile dysfunction drugs
Antipyretic analgesics >
Non-steroidal anti-inflammatory drugs Antipyretic and analgesic Anti-migraine drug Anti-gout medicine Analgesic
Antiallergic >
Allergic reaction medium blocker Antihistamine
Antiparasitic drug >
Anti-amebiasis and anti-trichomoniasis drugs Antimalarial Resistance to filariasis and anti-leishmaniasis Anti-fungal medicine Anthelmintic Antiprotozoal Anthelmintic
Antibiotics >
Beta-lactamase inhibitor Aminoglycoside Macrolide drug Peptide Polyene Rifamycin Lincosamide Other antibiotics Penicillin Tetracycline Cephalosporin Amide alcohol Agricultural antibiotics
Antineoplastic agents >
Hormone antineoplastic agents Antimetabolite antineoplastic Antibiotic antineoplastic agents Anti-tumor adjuvant Other antineoplastic agents Natural source antineoplastic agents Alkylating agent Tinic antineoplastic agents Idiopathic pulmonary fibrosis (IPF) treatment
Anesthetic Agents >
Skeletal muscle relaxant Local anesthetics General anesthetics
Urinary system medication >
Diuretic Diabetes insipidus medication Other urinary system medication Dehydrated medicine
Other chemicals >
other Health and epidemic prevention drugs
Synthetic anti-infective drugs >
Sulfonamides and synergists Antiviral drugs Anti-tuberculosis leprosy Antihelium drug Antifungal drugs Quinolone Natural source anti-infectives Disinfectant antiseptic Nitrofuran
Nervous system medication >
2 sedative and hypnotics Antiepileptic and anticonvulsant Anxiolytic Antipsychotic Antidepressant, manic Anti-shock palsy Brain metabolism regulating drug Cholinergic Other nervous system medication Central stimulant Parkinson's syndrome
Water, electrolyte and acid-base balance regulator >
Electrolyte balance regulator Glucose drug Acid-base balance regulator
Vitamins and minerals >
Trace elements and mineral drugs Vitamin AD drugs Vitamin B drugs Vitamin C drugs Nutritional health medicine
Digestive system medication >
Liver disease medication Acid and gastric mucosal protective drugs Biliary medicine Other digestive system medication Appetite suppressant and other diet pills Gastrointestinal drug Gastrointestinal expectorant Laxative antidiarrheal Inhibition of gastric acid secretion Antiemetic emetic Digestive drug
Blood system medication >
Leukocyte proliferative drug Platelet proliferative drug Anticoagulant and antiplatelet drugs Anti-anemia drug Blood volume expander Hemostatic drug
Circulatory system medication >
Regulating blood lipids Prevention and treatment of angina pectoris Calcium channel blocker Anti-congestive heart failure medicine Antihypertensive drug Antiarrhythmic drug Anti-shock vasoactive drug Other circulatory system medication Angiotensin converting enzyme and receptor inhibitor Peripheral vasodilator Beta-adrenergic receptor blocker Treatment of chronic cardiac insufficiency Anti-atherosclerosis
Diagnostic medication >
Organ function test agent Image inspection medication
Special medicine >
Radioisotope Antidote Stomatology medication Dermatology medication Surgical medication Ophthalmic medication
Drugs that affect tissue metabolism
Feed drug additive
Anti-stress drug
Immune function drug >
Immunomodulatory drug Immunosuppressive drug
Veterinary drug raw materials
Inhibitor
Common amino acids and protein drugs
Nucleic acid drug
Enzymes and coenzymes
Inhibitor >
Immune inhibitor Protein tyrosine kinase Neuronal Signaling PI3K/Akt/mTOR inhibitor (PI3K/Akt/mTOR) Metabolism Cell Cycle Epigenetics Cytoskeletal Signaling Angiogenesis DNA damage Proteases Apoptosis Mitogen-activated protein kinase (MAPK) Endocrinology & Hormones G protein coupled receptor(GPCR & G Protein) Transmembrane Transporters Tyrosine protein kinase/signal transducer and transcriptional activator inhibitor (JAK/STAT) TGF-beta/Smad signaling pathway inhibitor (TGF-beta/Smad) Stem Cells & Wnt Signaling Paths (Stem Cells & Wnt) Nuclear transcription factor (NF-κB) Ubiquitin inhibitor Microbiology Autophagy lysosome (Autophagy)
Biological response modifier
Fatty drug
Amino acids and their derivatives >
Arginine derivatives Asparagine derivatives Aspartic acid derivative Cysteine derivative Glutamine derivative Glutamic acid derivative Glycine derivatives Histidine derivative Isoleucine derivative Leucine derivative Lysine derivative Methionine derivatives Phenylalanine derivatives Proline derivatives Serine derivative Threonine derivative Tryptophan derivatives Tyrosine derivatives Proline derivatives Alanine derivatives Methionine derivatives BOC-amino acid Cbz-amino acid FMOC-amino acid --amino acid Other protected amino acids Amino alcohol derivative Amino acid salt Ester amino acid Other amino acid derivatives Natural amino acids and their derivatives
Carbohydrate >
Monosaccharide Oligosaccharide Polysaccharide Double sugar
Biochemical reagent >
Biological dye Acid-base indicator Adjuvant
Nucleoside drugs >
Nucleoside intermediate Deoxynucleotides and their analogues Nucleotides and their analogues
Condensing agent
Peptide
Natural product
Plant extracts
Chinese herbal medicine ingredients
Microbiological reagent
Protein research
antibody >
Antibody Enzyme secondary antibody Apoptosis and autophagy Cell metabolism Chromatin / epigenetic / cell cycle Cytoskeleton/extracellular matrix MAPK and PI3K/Akt pathway Neuroscience Immunity and inflammation PKC, calcium ion and lipid signaling pathway Stem cells, development and differentiation Protein translation, folding and degradation Other categories of primary antibodies
  • CAS Number: 405169-16-6
  • MF: C21H21FN6O
  • MW: 392.429
  • Catalog:FLT3 inhibitor
  • Density: 1.4±0.1 g/cm3
  • Boiling Point: N/A
  • Melting Point: N/A
  • Flash Point: N/A
  • CAS Number: 897016-82-9
  • MF: C26H29N3O3
  • MW: 431.527
  • Catalog:Src inhibitor
  • Density: 1.2±0.1 g/cm3
  • Boiling Point: 680.9±55.0 °C at 760 mmHg
  • Melting Point: N/A
  • Flash Point: 365.6±31.5 °C
  • CAS Number: 1265229-25-1
  • MF: C20H16N6O
  • MW: 356.38100
  • Catalog:FGFR inhibitor
  • Density: N/A
  • Boiling Point: N/A
  • Melting Point: N/A
  • Flash Point: N/A
  • CAS Number: 260415-63-2
  • MF: C21H16Cl2N4OS
  • MW: 443.349
  • Catalog:Bcr-Abl inhibitor
  • Density: 1.5±0.1 g/cm3
  • Boiling Point: 626.7±65.0 °C at 760 mmHg
  • Melting Point: N/A
  • Flash Point: 332.8±34.3 °C
  • CAS Number: 1229208-44-9
  • MF: C23H21N7O
  • MW: 411.459
  • Catalog:Syk inhibitor
  • Density: 1.5±0.1 g/cm3
  • Boiling Point: N/A
  • Melting Point: N/A
  • Flash Point: N/A
  • CAS Number: 717906-29-1
  • MF: C22H21F3N6O3S
  • MW: 506.501
  • Catalog:FAK inhibitor
  • Density: 1.5±0.1 g/cm3
  • Boiling Point: N/A
  • Melting Point: N/A
  • Flash Point: N/A
  • CAS Number: 1025687-58-4
  • MF: C23H24FN6Na2O9P
  • MW: 624.423
  • Catalog:Syk inhibitor
  • Density: N/A
  • Boiling Point: N/A
  • Melting Point: N/A
  • Flash Point: N/A
  • CAS Number: 931398-72-0
  • MF: C19H16N2O5
  • MW: 352.341
  • Catalog:HIF inhibitor
  • Density: 1.5±0.1 g/cm3
  • Boiling Point: 642.8±55.0 °C at 760 mmHg
  • Melting Point: N/A
  • Flash Point: 342.5±31.5 °C
  • CAS Number: 1242156-23-5
  • MF: C35H35FN6O3
  • MW: 606.689
  • Catalog:BTK inhibitor
  • Density: 1.4±0.1 g/cm3
  • Boiling Point: 868.6±65.0 °C at 760 mmHg
  • Melting Point: N/A
  • Flash Point: 479.1±34.3 °C
  • CAS Number: 852433-84-2
  • MF: C27H33FN6O7
  • MW: 572.59
  • Catalog:FLT3 inhibitor
  • Density: N/A
  • Boiling Point: N/A
  • Melting Point: N/A
  • Flash Point: N/A
  • CAS Number: 1000669-72-6
  • MF: C20H20N4O
  • MW: 332.399
  • Catalog:FLT3 inhibitor
  • Density: 1.3±0.1 g/cm3
  • Boiling Point: 604.1±55.0 °C at 760 mmHg
  • Melting Point: N/A
  • Flash Point: 319.1±31.5 °C
  • CAS Number: 901119-35-5
  • MF: C23H26FN6O9P
  • MW: 580.459
  • Catalog:Syk inhibitor
  • Density: 1.5±0.1 g/cm3
  • Boiling Point: 814.2±75.0 °C at 760 mmHg
  • Melting Point: N/A
  • Flash Point: 446.2±37.1 °C
  • CAS Number: 362-07-2
  • MF: C19H26O3
  • MW: 302.408
  • Catalog:HIF inhibitor
  • Density: 1.2±0.1 g/cm3
  • Boiling Point: 464.4±45.0 °C at 760 mmHg
  • Melting Point: 188-190°C
  • Flash Point: 234.7±28.7 °C
  • CAS Number: 1227158-85-1
  • MF: C26H26F3N7O2
  • MW: 525.526
  • Catalog:HIF inhibitor
  • Density: 1.5±0.1 g/cm3
  • Boiling Point: 677.7±65.0 °C at 760 mmHg
  • Melting Point: N/A
  • Flash Point: 363.7±34.3 °C
  • CAS Number: 1457983-28-6
  • MF: C25H25BrN6O2
  • MW: 521.409
  • Catalog:FLT3 inhibitor
  • Density: 1.487±0.06 g/cm3
  • Boiling Point: N/A
  • Melting Point: N/A
  • Flash Point: N/A
  • CAS Number: 856243-80-6
  • MF: C19H18BrN3O
  • MW: 384.270
  • Catalog:Bcr-Abl inhibitor
  • Density: 1.4±0.1 g/cm3
  • Boiling Point: 582.1±50.0 °C at 760 mmHg
  • Melting Point: N/A
  • Flash Point: 305.9±30.1 °C
  • CAS Number: 872511-34-7
  • MF: C26H31Cl2N7O3
  • MW: 560.475
  • Catalog:FGFR inhibitor
  • Density: 1.4±0.1 g/cm3
  • Boiling Point: 747.9±60.0 °C at 760 mmHg
  • Melting Point: N/A
  • Flash Point: 406.1±32.9 °C
  • CAS Number: 717907-75-0
  • MF: C21H20F3N7O3S
  • MW: 507.489
  • Catalog:FAK inhibitor
  • Density: 1.5±0.1 g/cm3
  • Boiling Point: N/A
  • Melting Point: N/A
  • Flash Point: N/A